BRISTOL MYERS SQUIBB

🇫🇷France

Country: 🇫🇷France

Ownership: -

Established: 1989-01-01

Employees: 30K

Market Cap: $97.5B

Website: https://www.bms.com/

Clinical Trials

An Investigational Study of Cyclosporine on Experimental Medication BMS-986165 in Healthy Male Participants

Phase 1

Completed

Conditions: Psoriasis

Interventions: Drug: BMS-986165
Drug: Cyclosporine

First Posted Date: 2018-02-05

Last Posted Date: 2020-03-18

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 54

Registration Number: NCT03419910

Locations: 🇺🇸
PRA Health Sciences, Salt Lake City, Utah, United States

A Study of Experimental Medication BMS-986263 in Adults With Advanced Hepatic Fibrosis After Cure of Hepatitis C

Phase 2

Completed

Conditions: Hepatic Cirrhosis
Liver Fibrosis

Interventions: Other: Placebo
Drug: BMS-986263

First Posted Date: 2018-02-05

Last Posted Date: 2022-02-04

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 61

Registration Number: NCT03420768

Locations: 🇺🇸
The Texas Liver Institute, San Antonio, Texas, United States

Safety and Effectiveness of Abatacept in Psoriatic Arthritis Participants

Completed

Conditions: Psoriatic Arthritis (PsA)

First Posted Date: 2018-02-01

Last Posted Date: 2022-05-31

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 190

Registration Number: NCT03419143

Locations: 🇩🇪
Local Institution - 0001, Nurnberg, Germany

An Immuno-Therapy Study of Experimental Medication BMS-986205 Given With Nivolumab With or Without Chemotherapy Compared to Chemotherapy in Participants With Previously Untreated Stage IV or Recurrent Non-Small Cell Lung Cancer

Phase 3

Withdrawn

Conditions: Non-Small Cell Lung Cancer
Lung Cancer

Interventions: Drug: BMS-986205
Biological: Nivolumab
Drug: Chemotherapy

First Posted Date: 2018-01-31

Last Posted Date: 2018-04-30

Lead Sponsor: Bristol-Myers Squibb

Registration Number: NCT03417037

Locations: 🇹🇷
Local Institution, Istanbul, Turkey

An Investigational Immunotherapy Study of Nivolumab With Standard of Care Therapy vs Standard of Care Therapy for First-Line Treatment of Colorectal Cancer That Has Spread

Phase 2

Completed

Conditions: Colorectal Cancer

Interventions: Biological: Nivolumab
Drug: Oxaliplatin
Drug: Leucovorin
Drug: Fluorouracil
Drug: Bevacizumab

First Posted Date: 2018-01-30

Last Posted Date: 2023-11-18

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 196

Registration Number: NCT03414983

Locations: 🇺🇸
Local Institution - 0033, Arlington Heights, Illinois, United States
🇺🇸
Local Institution - 0005, Philadelphia, Pennsylvania, United States
🇺🇸
Uab Comprehensive Cancer Center, Birmingham, Alabama, United States

and more 46 locations

A Dose-Escalation Study of MDX-010 Administered Monthly as Immunotherapy in Subjects Infected With Human Immunodeficiency Virus (HIV)

Phase 1

Completed

Conditions: Human Immunodeficiency Virus (HIV)

Interventions: Biological: MDX-010

First Posted Date: 2018-01-23

Last Posted Date: 2018-01-23

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 24

Registration Number: NCT03407105

Locations: 🇺🇸
Orlando Immunology Center, Orlando, Florida, United States
🇺🇸
Quest Clinical Research, San Francisco, California, United States
🇺🇸
Tower ID Medical Associates, Los Angeles, California, United States

and more 2 locations

A Study to Investigate BMS-986165 and Methotrexate in Healthy Male Patients

Phase 1

Completed

Conditions: Lupus
Psoriatic Arthritis

Interventions: Drug: Methotrexate
Drug: Leucovorin
Drug: BMS-986165

First Posted Date: 2018-01-18

Last Posted Date: 2020-02-25

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 30

Registration Number: NCT03402087

Locations: 🇳🇱
PRA Health Sciences, Groningen, Netherlands

A Sub-study of BMS-986036 in Subjects With Non-Alcoholic Steatohepatitis (NASH)

Phase 2

Completed

Conditions: Non-Alcoholic Steatohepatitis

Interventions: Drug: Placebo
Drug: BMS-986036

First Posted Date: 2018-01-17

Last Posted Date: 2021-02-26

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 3

Registration Number: NCT03400163

Locations: 🇺🇸
Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, United States
🇺🇸
Texas Liver Institute, San Antonio, Texas, United States

A Study of BMS-986253 in Combination With Nivolumab or Nivolumab Plus Ipilimumab in Advanced Cancers

Phase 1

Active, not recruiting

Conditions: Cancer
Melanoma

Interventions: Drug: BMS-986253
Biological: Nivolumab
Biological: Ipilimumab
Other: Placebo

First Posted Date: 2018-01-17

Last Posted Date: 2024-07-17

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 281

Registration Number: NCT03400332

Locations: 🇺🇸
Local Institution - 0007, Lakewood, Colorado, United States
🇺🇸
Local Institution - 0087, Atlanta, Georgia, United States
🇺🇸
Local Institution - 0025, New York, New York, United States

and more 69 locations

An Immuno-therapy Study of Nivolumab in Combination With Experimental Medication BMS-986205 Compared to Standard of Care EXTREME Regimen in First-line Recurrent/Metastatic Squamous Cell Carcinoma of Head and Neck

Phase 3

Withdrawn

Conditions: Head and Neck Cancer

Interventions: Biological: Nivolumab
Biological: Cetuximab
Drug: BMS-986205
Drug: Cisplatin
Drug: Carboplatin
Drug: Fluorouracil

First Posted Date: 2017-12-29

Last Posted Date: 2019-04-18

Lead Sponsor: Bristol-Myers Squibb

Registration Number: NCT03386838

Locations: 🇺🇸
Allegheny General Hospital, Pittsburgh, Pennsylvania, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy